Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 2 institutions in 2 countries.
Benjamin Bruno PolicicchioCenter for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Paola SetteCenter for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Cuiling XuCenter for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
George Haret-RichterCenter for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Tammy DunsmoreCenter for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Ivona PandreaCenter for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Ruy M RibeiroTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Cristian ApetreiCenter for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.ORCID 0000-0002-0322-7185
University of Pittsburgh · USLos Alamos National Laboratory · US
Funding
SIV Pathogenesis in African Green Monkeys and Pigtailed MacaquesR01HL117715 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VASILE PANDREA, IVONA · 2012 to 2021
$7.0M
Interventions to Reduce Hypercoagulability in Old SIV-Infected NHPsR01HL123096 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VASILE PANDREA, IVONA · 2015 to 2025
$6.8M
Animal Model for Testing SIV Latency Reversal StrategiesR01AI119346 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI APETREI, CRISTIAN · 2015 to 2019
$3.4M
PITT AIDS RESEARCH TRAINING PROGRAMT32AI065380 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BARRATT-BOYES, SIMON M · 2005 to 2020
$3.2M
Quantifying Immune VS. Viral Killing of SIV Infected and Latently Infected CellsR01AI104373 · NIAID · LOS ALAMOS NAT SECTY-LOS ALAMOS NAT LAB · PI RIBEIRO, RUY M · 2013 to 2016
Two SIVmac251-infected rhesus macaques received tenofovir/emtricitabine with raltegravir intensification. Viral rebound occurred during treatment and sequencing of reverse transcriptase and integrase genes identified multiple resistance mutations. Similar to HIV infection, antiretroviral-resistance mutations may occur in SIV-infected nonhuman primates receiving nonsuppressive ART. As ART administration to nonhuman primates is currently dramatically expanding, fueled by both cure research and the study of HIV-related comorbidities, viral resistance should be factored in the study design and data interpretation.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Emergence of resistance mutations in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving non-suppressive antiretroviral therapy (ART). · full record | OpenQuestion